Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immucor/Gamma Biologicals

This article was originally published in The Gray Sheet

Executive Summary

Merger agreement valued at $25 mil. calls for Immucor to launch a cash tender offer for all outstanding GB shares at $5.40 each. The combination would make Immucor "the market leader in providing blood serology reagents and systems in the U.S. and Canada, and will greatly strengthen its international market position," Immucor states. The tender offer, begun Sept. 25, is expected to close Oct. 23, whereupon GB will become a wholly owned subsidiary of Immucor. Stock in GB, which posted fiscal 1998 revenues of $18 mil., closed at $3 on Sept. 18, the last trading day before the announcement

You may also be interested in...



Diagnostics In Brief

Siemens/Dade deal: Siemens expects to close its $7 billion acquisition of diagnostics firm Dade Behring Nov. 6, ahead of initial expectations. The announcement follows expiration of the $77 per share cash tender offer on Oct. 31. Dade CEO Jim Reid-Anderson will become the new chief of Siemens Medical Solutions Diagnostics. The division is currently headed by Tony Bihl, former president of Bayer Diagnostics, which Siemens acquired in January. Primary offices will be located at Dade's headquarters in Deerfield, Ill. Dade recently reported third-quarter sales of $475 million, up 12% over the prior-year period. Upon completion of the deal, Siemens is expected to overtake Roche Diagnostics as the in vitro diagnostics market leader (1"The Gray Sheet" July 30, 2007, p. 4)

Pfizer’s Expected 2020 COVID-19 Vaccine Production Fell By 50% After Scaleup Delays

Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel